1. Home
  2. Clinical Topics
  3. FDA approves first treatment for acquired TTP
Clinical TopicsDrugs and DevicesWeb Exclusives
treatment acquired ttp

FDA approves first treatment for acquired TTP

Share

On Feb. 6, the FDA approved Cablivi (caplacizumab-yhdp) injection, the first therapy indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP).

Read more via U.S. Food & Drug Administration.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts